Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... our research has shown that we can ...

All told, Lilly stock still gained 33% in 2024 ... Mounjaro and Zepbound. For the fourth quarter, Lilly calls for revenue of $3.5 billion for Mounjaro and $1.9 billion for Zepbound.

Results for the fourth quarter of 2024 should show revenue ... The problem, however, goes back to valuation. Eli Lilly is a stock which you might consider to be "priced to perfection" because ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...